Kami Maddocks
Overview
Explore the profile of Kami Maddocks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chowdhury S, Bhatta S, Voorhees T, Annunzio K, Bond D, Sawalha Y, et al.
J Hematol Oncol
. 2025 Jan;
18(1):4.
PMID: 39757235
Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample size precluding robust...
2.
Sawalha Y, Maddocks K
Hematology Am Soc Hematol Educ Program
. 2024 Dec;
2024(1):34-41.
PMID: 39644043
Historically considered a lymphoma with limited treatment options and poor outcomes, the treatment landscape in mantle cell lymphoma (MCL) has evolved remarkably in the last decade. Chemoimmunotherapy (CIT) remains the...
3.
4.
Roeker L, Coombs C, Shah N, Jurczak W, Woyach J, Cheah C, et al.
Acta Haematol
. 2024 Jun;
:1-17.
PMID: 38824917
Introduction: Pirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor, has demonstrated promising efficacy in B-cell malignancies and is associated with low rates of discontinuation and dose reduction. Pirtobrutinib...
5.
6.
Mei M, Tsai N, Palmer J, Armenian S, Chen R, Rosen S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(8):537-542.
PMID: 38693037
Introduction: Brentuximab vedotin (BV) is an antibody-drug conjugate that delivers monomethyl auristatin E (MMAE) to CD30+ cells and is safe and effective in relapsed/refractory (r/r) Hodgkin lymphoma (HL). Although most...
7.
Denlinger N, Song N, Zhang X, Jeon H, Peterson C, Wang Y, et al.
Blood Adv
. 2024 Apr;
8(12):3140-3153.
PMID: 38607381
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Robust biomarkers and a complete understanding of CAR T-cell function in the postinfusion phase remain...
8.
Nalin A, Zhao Q, Voorhees T, Bond D, Sawalha Y, Hanel W, et al.
Front Oncol
. 2023 Oct;
13:1264387.
PMID: 37781209
Given the paucity of data surrounding the prognostic relevance of circulating lymphoma (CL) in Waldenström macroglobulinemia (WM), we sought to evaluate the impact of CL at diagnosis on outcomes in...
9.
Qualls D, Lambert N, Caimi P, Merrill M, Pullarkat P, Godby R, et al.
Blood
. 2023 Sep;
142(26):2327-2331.
PMID: 37738563
In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and...
10.
Wang M, Jurczak W, Zinzani P, Eyre T, Cheah C, Ujjani C, et al.
J Clin Oncol
. 2023 May;
41(24):3988-3997.
PMID: 37192437
Purpose: Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi)...